Huong Giang Ta
Max K. Leong
*The final, formatted version of the article will be published soon.
PERSPECTIVE article
Front. Pharmacol.
Sec. Predictive Toxicology
Volume 15 - 2024 |
doi: 10.3389/fphar.2024.1496630
Mitigating Paxlovid TM -Induced Drug-Drug Interaction Toxicity: An In Silico Insight ‡
Provisionally accepted- National Dong Hwa University, Shoufeng, Hualien County, Taiwan
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid TM , have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid TM combination. In this study, the skin permeability potential of Nirmatrelvir was assessed using various in silico models. The prediction results suggest that Nirmatrelvir could be administrated via the transdermal route, offering a promising avenue to enhance the efficacy of anti-COVID-19 agents.
Keywords: in silico, Skin permeability, PAXLOVID, nirmatrelvir, COVID-19
Received: 15 Sep 2024; Accepted: 15 Nov 2024.
Copyright: © 2024 Ta and Leong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Max K. Leong, National Dong Hwa University, Shoufeng, 97401, Hualien County, Taiwan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.